drug
Parkinson's Disease
Preclinicalupdated 6mo agoby Metallomix Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 7- tagParkinson's Disease8 co-mentions · 8 sources
- company$OVIDOvid Therapeutics Inc.1 co-mentions · 1 sources
- companyMassachusetts General Hospital1 co-mentions · 1 sources
- companyBeijing Tiantan Hospital1 co-mentions · 1 sources
- drugOV-40711 co-mentions · 1 sources
- drugXS-4111 co-mentions · 1 sources
- drugDNL-1511 co-mentions · 1 sources
indications
indications
Parkinson's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying Parkinson's Disease
News(10)
- Valo and Montai become one as the Flagship AI-based biotechs tie the knotTwo Flagship Pioneering-founded AI drug discovery and development biotechs, Valo Health and Montai Therapeutics, will join forces in a merger that aims to advance Montai’s early-stage and preclinic…fiercebiotech · 6d ago
- Aspen Neuroscience lands $141M IPO, while Bambusa secures $169MA Parkinson’s cell therapy biotech and an I&I startup from former BioNTech leaders joined the public markets on Friday, extending a sizzling IPO streak for drug developers. Aspen Neuroscience raise…endpoints · 18d ago
- Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectationsEli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…fiercebiotech · 19d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.fiercebiotech · 21d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.fiercebiotech · 1mo ago
- Parkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOsA Gilead-backed cell therapy maker and an I&I biotech from BioNTech vets are looking to ride the biotech industry's IPO momentum. Aspen Neuroscience and Bambusa Therapeutics are the latest drug dev…endpoints · 1mo ago
- Cerevance rescues its Parkinson's drug with phase 3 winCerevance's oral non-dopaminergic therapy has redeemed itself by improving both motor and non-motor symptoms in a phase 3 Parkinson's disease study.fiercebiotech · 1mo ago
- Roche enlists Alector in Parkinson's deal, paying $100M upfrontAlector is teaming up with another large drugmaker, fresh off the collapse of a separate partnership. Alector will get $100 million upfront from Roche in a deal centered on the biotech’s neuroscien…endpoints · 1mo ago
- Genentech pays Alector $100M for preclinical Parkinson’s prospectGenentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.fiercebiotech · 1mo ago
- AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approvalThe FDA approved AbbVie’s tavapadon, a next-generation therapy for Parkinson’s disease that's expected to provide the symptom relief of its predecessors but with fewer side effects. The dopamine ag…endpoints · 1mo ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that